MONTREAL, QUEBEC--(MARKET WIRE)--Jun 14, 2007 -- Mistral Pharma Inc. (CDNX:MIP.V - News) (the “Corporation”, “Mistral”) announces today its financial results and review of operating highlights for the year ended March 31, 2007. “The highlights of Mistral’s second year as a publicly traded company were the successful pilot clinical trial of its MIST-B02 product, the realization of the successful private placement of $5 million that closed in May 2006 and the closing of a working capital loan of US $ 1.5 million with MMV Financial Inc. in the fall of 2006,” said Mr. Bertrand Bolduc, the Corporation’s President & CEO. “These achievements, combined with the recent acquisition of CuraMedica (Canada) Inc., the approval of Instillagel® by Health Canada and the announcement that we have entered into exclusive discussions with a strategic partner for the co-development and commercialization of MIST-B01 for the US market, demonstrate our commitment to becoming an important development and marketing partner for pharmaceutical companies,” he added.
